Tembexa has two formulations, a 100mg tablet form and 10mg/mL oral suspension, indicated to be administered once a week for two weeks.
In June last year, the US Food and Drug Administration (FDA) granted approval for the antiviral therapy to treat human smallpox disease in adult as well as paediatric patients, including neonates.
Chimerix entered a ten-year contract worth up to $680m with the US Government in August this year for delivering up to 1.7 million courses of the tablet and suspension formulations of Tembexa.
This deal comprises an initial product procurement of nearly $115m as well as an option for further procurement worth up to nearly $551m, exercisable at the Biomedical Advanced Research and Development Authority’s (BARDA) discretion.
Apart from product purchase, the contract also includes $12m worth of reimbursed post-marketing activities.
In accordance with the final BARDA contract, Emergent will make $238m in upfront payment to Chimerix.
Chimerix is entitled to receive milestone payments of up to $124m subject to the government exercising procurement options after the base period.
Additionally, Chimerix will receive 20% and 15% royalty on gross profit from Tembexa sales in and outside the US, respectively
Emergent will also make a further payment of up to $12.5m on Chimerix, meeting certain development-based milestones.
Emergent government/MCM business senior vice-president Paul Williams said: “The addition of Tembexa to our smallpox medical countermeasure franchise, which consists of our smallpox vaccine and therapeutic for smallpox vaccine complications, creates a more comprehensive offering to combat this deadly public health threat.
“We look forward to supporting the US Government’s smallpox preparedness strategy on a broader scale by executing on this BARDA contract.”